CureVac Q4 2020 results and business update

 - COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission

- Pivotal Phase 2b/3 in Europe and Latin America fully recruited with over 40,000 participants. Interim analysis for vaccine efficacy expected in Q2 2021

- Phase 2a trial in Peru and Panama amended for addition of secondary endpoint for vaccine efficacy in total population with a focus on participants over the age of 60

- CVnCoV demonstrates, in preclinical challenge study, full protection from infections with Variant of Concern B.1.351 (South Africa variant)

- Expanding COVID-19 vaccine program: Three new CVnCoV studies in specific populations expected to be initiated soon

- Advancing the commercial organization and preparing access to commercial territories

- Expanded manufacturing network with European partners expected to manufacture up to 300 million doses of CVnCoV by end of 2021 and up to one billion doses in 2022

- Partnerships with Bayer, GSK and the UK government (partnership under final discussions) to rapidly advance first-generation vaccines and expand into second-generation vaccines in our COVID-19 program

- Oncology lead asset CV8102: Phase 1 expansion cohort initiated with preferred dose in patients with advanced melanoma

- Financials:

- Cash position of €1.32 billion as of December 31, 2020

- Additional $517.5 million in gross proceeds based on issuance of 5,750,000 common shares from February 2021 capital raise

https://finance.yahoo.com/news/curevac-announces-financial-results-business-114500783.html